Cancer and Metastasis Reviews

, Volume 30, Issue 1, pp 97–109

Immunomodulating antibodies and drugs for the treatment of hematological malignancies

  • Roch Houot
  • Holbrook Kohrt
  • Matthew J. Goldstein
  • Ronald Levy
Article

DOI: 10.1007/s10555-011-9274-3

Cite this article as:
Houot, R., Kohrt, H., Goldstein, M.J. et al. Cancer Metastasis Rev (2011) 30: 97. doi:10.1007/s10555-011-9274-3

Abstract

The aim of cancer immunotherapy is to induce immune cells to kill tumor and promote immunological memory that protects against tumor recurrence. Most current immunotherapies, such as monoclonal antibodies (mAb), target the tumor cells directly. Advances in our understanding of the immune system such as the role of co-stimulatory and co-inhibitory receptors, and the advent of new immunomodulatory agents provide new opportunities to target the immune system and enhance anti-tumor immune responses. These promising agents include immunomodulating mAbs, Toll-like receptor agonists, IMiDs, and cytokines. In this review, we discuss the current results of immunomodulating agents in the treatment of hematological malignancies and propose applications that include targeting of the innate and adaptive immune systems as well as combinations with tumor-specific mAbs.

Keywords

ImmunomodulationImmunotherapyMonoclonal antibodiesCytokineCpGThalidomideLenalidomideCancerHematological malignanciesLymphomaLeukemiaMyeloma

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Roch Houot
    • 1
  • Holbrook Kohrt
    • 2
  • Matthew J. Goldstein
    • 2
  • Ronald Levy
    • 2
  1. 1.Service d’Hématologie Clinique & INSERM U917Centre Hospitalier Universitaire de RennesRennesFrance
  2. 2.Department of Medicine, Division of OncologyStanford UniversityStanfordUSA